lipid-a has been researched along with Whooping-Cough* in 3 studies
1 review(s) available for lipid-a and Whooping-Cough
| Article | Year |
|---|---|
No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.
Development of non-infectious subunit vaccines is hampered by a slow pipeline of new adjuvants to replace or enhance alum in part because expectations of safety are high. Transient vaccine side effects are not clinical priorities because they cause no lasting harm and vaccine development has appropriately been focused on avoidance of serious adverse events. As a result, surprisingly little is known about the extent to which side effects caused by a vaccine's reactogencicity are predictive of successful immunization outcomes. Recent clinical studies of pertussis and human papillomavirus vaccines adjuvanted with alum or the TLR4 agonist monophosphoryl lipid A can be used to advance understanding of the relationship between vaccine side effects and immunization outcomes. Topics: Adjuvants, Immunologic; Alum Compounds; Antibodies, Viral; Diphtheria-Tetanus-acellular Pertussis Vaccines; Drug-Related Side Effects and Adverse Reactions; Humans; Lipid A; Pain; Papillomavirus Infections; Papillomavirus Vaccines; Toll-Like Receptor 4; Treatment Outcome; Vaccination; Whooping Cough | 2017 |
2 other study(ies) available for lipid-a and Whooping-Cough
| Article | Year |
|---|---|
DAT, deacylating autotransporter toxin, from
The pathogenic bacteria Topics: Bordetella parapertussis; Bordetella pertussis; Cough; Humans; Lipid A; Lipopolysaccharides; Pertussis Toxin; Toxins, Biological; Type V Secretion Systems; Whooping Cough | 2023 |
Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses.
Lipopolysaccharide (LPS) is one of the main constituents of the Gram-negative bacterial outer membrane. Besides being an endotoxin, LPS also possesses a powerful adjuvant activity. Previously, it has been shown that changes in the chemical composition of the lipid A domain of LPS modulate its biological activity. For example, monophosphoryl lipid A (MPL) has been shown to be a non-toxic immunostimulatory compound. Moreover, several LPS analogs have been shown to antagonise LPS-induced signalling in eukaryotic cells. In the present study, we show that supplementation of a whole-cell pertussis (wP) vaccine with LPS analogs modulates the vaccine-induced immune responses. We show in a mouse-model system that addition of MPL to a wP vaccine increases vaccine efficacy without altering vaccine-induced serum pro-inflammatory cytokine levels. Furthermore, we show that Neisseria meningitidis LpxL2 LPS, an LPS species derived from a N. meningitidis lpxL2 mutant, antagonises wP and LPS-stimulated interleukin-6 (IL-6) production by macrophages in vitro, and that addition of this LPS-derivative to the wP vaccine decreases vaccine-induced serum IL-6 levels and increases vaccine efficacy. Topics: Adjuvants, Immunologic; Animals; Antibodies, Bacterial; Bordetella pertussis; Cell Line; Cytokines; Female; Interleukin-6; Lipid A; Lipopolysaccharides; Lung; Macrophage Activation; Macrophages; Mice; Neisseria meningitidis; Pertussis Vaccine; Treatment Outcome; Whooping Cough | 2008 |